Pure Global
NCT06264752

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury (MEnD-AKI)
University of Pittsburgh·ClinicalTrials.gov·otherEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
Level A
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University of Pittsburgh
Location
Altoona,Farrell,McKeesport,New Castle,Pittsburgh,Pittsburgh,Pittsburgh,Williamsport, United States of America
Timeline & enrollment
Phase
N/A
Start date
Feb 15, 2024
End date
Apr 01, 2026
Enrollment
625 participants
Primary outcome

Major Adverse Kidney Events within 30 days of randomization (MAKE30)

Summary

This study is a randomized controlled trial at eight hospitals within the University of
 Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical
 surveillance system augmented with real-time predictive analytics to support a pharmacist-led
 intervention delivered to attending physicians (primary service) to reduce the progression
 and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU)
 adults.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06264752
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06264752 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Pittsburgh and is currently Enrolling by invitation. The study focuses on Acute Kidney Injury. Target enrollment is 625 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.